He has disseminated his findings in over 60 scholarly articles and several U.S. patents as a co-inventor.
SCITUATE, MA, May 30, 2024 /24-7PressRelease/ -- Mario DiPaola has been selected for inclusion in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
Dr. DiPaola is a distinguished figure in the biotechnology industry. Since 2021, he has been the co-founder and chief executive officer of a biotechnology start-up, Therabene Inc. At Therabene Inc, he focuses on developing treatments for triple-negative breast cancer and pancreatic cancer, showcasing his commitment to addressing some of the most challenging diseases. One year after establishing his company, Dr. DiPaola became the head of research at Akttyva Therapeutics, a National Science Foundation-funded biotechnology research company in Boston, where his leadership and expertise have significantly contributed to its research initiatives.
A serial entrepreneur, Dr. DiPaola founded Epic Consulting as the firm's president and founder in 2006. Subsequently, he launched Blue Stream Laboratories Inc. as the founder, chief scientific officer, and chief operating officer, which he formed in 2006 and led for over a decade before it was acquired by Charles River Laboratories in 2016. From 2020 to 2021, Dr. DiPaola continued to operate Epic Pharma Consulting, offering strategic guidance and operational insights to clients in the pharmaceutical sector as a principal consultant.
Dr. DiPaola's career began with foundational roles at several notable organizations, including Antigenics, where he was the senior director of operations from 2001 to 2005 and earlier contributions at Biogen between 1998 and 2001.
Throughout his distinguished career, Dr. DiPaola has been involved in developing several approved therapeutics, including Alferon-N, Amevive, and Sucraid. As a seasoned researcher, he has disseminated his findings in over 60 scholarly articles and several U.S. patents as a co-inventor.
Outside of his primary career endeavors, Dr. DiPaola is actively involved with Mansfield Bio-Incubator Inc., reflecting his commitment to fostering innovation and supporting emerging talents in the biotechnology sector.
Dr. DiPaola's robust academic background includes a Bachelor of Science in chemistry from Queens College at the City University of New York, a Master of Business Administration in finance from Baruch College, and a Doctor of Philosophy in chemistry with a focus on biophysics from New York University. Furthering his expertise, he completed postdoctoral studies in biochemistry and neuroscience at Columbia University and pharmacology at New York University.
Dr. DiPaola plans to continue focusing on Therabene Inc's mission to develop groundbreaking treatments for cancer patients. Through his leadership and dedication to saving lives, he aims to grow the company and bring its innovative solutions to market, significantly impacting health care worldwide. In recognition of his accomplishments, Dr. DiPaola was featured in World Leaders Magazine. His success can be attributed to his hard work, persistence, and passion for science, which drives him to overcome challenges in pursuit of meaningful achievements.
About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Marquis celebrates its 125th anniversary in 2023, and Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis® publications may be visited at the official Marquis Who's Who® website at www.marquiswhoswho.com.
# # #